Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7718640 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
Mar, 2027
(3 years from now) | |
US8338395 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
May, 2027
(3 years from now) |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 05 March, 2014
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: INJECTABLE;INTRAMUSCULAR
3
United States
2
Korea, Republic of
2
Denmark
2
ME
2
Russia
2
China
2
South Africa
2
European Union
1
Colombia
1
Ecuador
1
Iceland
1
Australia
1
EA
1
Israel
1
Croatia
1
IB
1
Canada
1
Yugoslavia
1
New Zealand
1
Spain
1
Uruguay
1
Peru
1
Saudi Arabia
1
Costa Rica
1
Austria
1
Chile
1
Jordan
1
Portugal
1
Ukraine
1
Poland
1
Japan
1
Norway
1
Hong Kong
1
Germany
1
Mexico
1
Slovenia
1
Argentina
1
Brazil
1
Taiwan
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9107827 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(10 months from now) | |
US9101549 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(10 months from now) | |
US9101540 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(10 months from now) | |
US9040088 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(10 months from now) | |
US7101576 | ENDO PHARMS INC | Nanoparticulate megestrol formulations |
Apr, 2024
(10 months from now) |
Drugs and Companies using MEGESTROL ACETATE ingredient
Market Authorisation Date: 05 July, 2005
Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)
Dosage: SUSPENSION;ORAL
20
United States
6
European Union
5
Japan
3
Canada
3
Australia
1
Mexico
1
Slovenia
1
Cyprus
1
Brazil
1
China
1
South Africa
1
EA
1
Denmark
1
Portugal
1
Spain
1
Norway
1
Austria
1
Korea, Republic of
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8940714 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Feb, 2024
(8 months from now) | |
US7404489 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Mar, 2024
(9 months from now) | |
US9415007 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Jul, 2024
(1 year, 1 month from now) | |
US7229636 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(1 year, 1 month from now) | |
US7879349 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(1 year, 1 month from now) | |
US8003353 | ENDO PHARMS INC | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(1 year, 1 month from now) |
Drugs and Companies using CYANOCOBALAMIN ingredient
Market Authorisation Date: 31 January, 2005
Treatment: Cyanocobalamin administration through nasal infusion; Supplement for vitamin b12 deficiencies; Nasal administration of cyanocobalamin
Dosage: SPRAY, METERED;NASAL
9
United States
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic